Journal Article (Review Article)

DKFZ-2021-00326

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy.

Richardson, J. R. ; Schöllhorn, A. ; Gouttefangeas, C.DKFZ* ; Schuhmacher, J.

2021
MDPI Basel

This record in other databases:  

Please use a persistent id in citations: doi:10.3390/cancers13040596

Abstract: Cancer immunotherapy activates the immune system to specifically target malignant cells. Research has often focused on CD8+ cytotoxic T cells, as those have the capacity to eliminate tumor cells after specific recognition upon TCR-MHC class I interaction. However, CD4+ T cells have gained attention in the field, as they are not only essential to promote help to CD8+ T cells, but are also able to kill tumor cells directly (via MHC-class II dependent recognition) or indirectly (e.g., via the activation of other immune cells like macrophages). Therefore, immunotherapy approaches have shifted from only stimulating CD8+ T cells to targeting and assessing both, CD4+ and CD8+ T cell subsets. Here, we discuss the various subsets of CD4+ T cells, their plasticity and functionality, their relevance in the antitumor immune response in patients affected by cancer, and their ever-growing role in therapeutic approaches for human cancer.

Keyword(s): CD4+ T cells ; immunotherapy ; tumor

---

Contributing Institute(s):

1. DKTK TU AG Krebs-Immuntherapie (TU03)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2021

---

Database coverage:
; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---